MedPath

A New Treatment of Retinitis Pigmentosa

Not Applicable
Conditions
Retinitis Pigmentosa
Interventions
Procedure: retrobulbar injection of autoserum
Procedure: retrobulbar injection of placebo
Registration Number
NCT03998384
Lead Sponsor
Aier School of Ophthalmology, Central South University
Brief Summary

This study is designed to assess and to evaluate the therapeutic effect of retrobulbar injection of autoserum in the treatment of retinitis pigmentosa.

Detailed Description

The retinitis pigmentosa(RP) is an hereditary disease which causes visual deficiency leading to blindness. The methods of treatment include gene therapy, stem cell therapy and visual prothesis, etc. But all these methods own limitations can not be conquered in a short period. It was proved that vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) decreased in the aqueous humor of patients of RP. But the traditional exogenous nerve growth factors (NGFs) were immunogenic proteins and may cause inflammation. Autoserum contain a large amount of active factors and will not cause exclusive reaction. In this study we aim to assess and to evaluate the therapeutic effect and the safety of retrobulbar injection of autoserum in the treatment of retinitis pigmentosa.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Clinical diagnosis of retinitis pigmentosa
Exclusion Criteria
  • Suspected glaucoma, suspected optic nerve disease, blindness due to other ocular disease
  • Combined with serious systemic disease
  • Can not cooperate with the interventions and examinations.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group of autoserumretrobulbar injection of autoserumOne of two eyes of one patient which is assessed to have more serious retinal atrophy will receive the retrobulbar injection of autoserum.
group of placeboretrobulbar injection of placeboThe other eye which is assessed to have milder retinal atrophy will receive the retrobulbar injection of saline solution.
Primary Outcome Measures
NameTimeMethod
Change of the visual acuityone day before injection, one day, one month, three months and six months after surgery

To measure the visual acuity with logarithmic visual chart.

Change of the electrophysiological detection (electro-oculogram)one day before injection, three months and six months after surgery

To evaluate the retinal function with the use of electro-oculogram (EOG)

Change of the contrast sensitivityone day before injection, one month, three months and six months after surgery

To access the change of contrast sensitivity in different special frequency.

Change of the electrophysiological detection (flash electroretinogram)one day before injection, three months and six months after surgery

To evaluate the retinal function with the use of flash electroretinogram (F-ERG).

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath